Core Insights - Telomir Pharmaceuticals, Inc. has announced new cellular study results indicating that Telomir-1, in the form of Telomir-Zn, modulates intracellular metal balance linked to oxidative stress and mitochondrial dysfunction [1] Group 1: Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics targeting biological mechanisms involved in cancer, aging, and degenerative diseases [1] Group 2: Study Findings - The study demonstrates that Telomir-Zn induces a rapid and coordinated intracellular redistribution of zinc and iron [1] - The modulation of metal balance occurs without relying on cytotoxic mechanisms, suggesting a novel approach to addressing oxidative stress and genomic integrity [1]

Core Viewpoint - Telo Genomics Corp. is conducting a non-brokered private placement offering of secured convertible debentures for gross proceeds of up to $1,200,000 to fund lab trials and general working capital [1][3]. Group 1: Offering Details - The debentures will have an interest rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date [2]. - Holders of the debentures can convert them into common shares at a conversion price of $0.05 per share before the maturity date [2]. - For every $100,000 of convertible debentures issued, Telo Genomics will issue 2 million detachable warrants, each exercisable at $0.08 per share for 12 months [2]. Group 2: Use of Proceeds - Proceeds from the offering are expected to be allocated for lab trials and general working capital [3]. Group 3: Company Overview - Telo Genomics is a biotech company specializing in a comprehensive telomere platform with applications in oncology and neurological diseases, focusing on liquid biopsies [4]. - The company combines expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to develop diagnostic products [4]. - Telo Genomics has substantiated its technology through over 160 peer-reviewed publications and 30+ clinical studies involving more than 3,000 patients [4].

Coinbase Global Inc. (NASDAQ:COIN)  CEO Brian Armstrong said Monday that his longevity startup, NewLimit, is working on extending human lifespan by treating age-related diseases.Can Aging Diseases Be Erased?Armstrong said in an X post that the new venture’s goal is to extend healthspan by restoring the function cells had when they were younger.“The thing that got me excited about that was like all these major diseases are correlated with aging,” Armstrong shared a clip from his recent podcast with Rick Robi ...

Core Viewpoint - Telomir Pharmaceuticals, Inc. has announced positive results from its GLP toxicology and safety pharmacology studies for its lead candidate, Telomir-1, indicating no treatment-related adverse toxicity and consistent systemic exposure following oral administration [1] Group 1: Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies targeting epigenetic and metabolic drivers of cancer and age-related diseases [1] Group 2: Study Results - The comprehensive series of IND-enabling GLP studies showed no treatment-related adverse toxicity [1] - Consistent systemic exposure was observed following oral administration of Telomir-1 [1]

Core Findings - Telomir Pharmaceuticals has expanded the oncology profile of its investigational compound Telomir-1 to include aggressive human leukemia cells, in addition to its previously reported efficacy in triple-negative breast cancer, pancreatic cancer, and aggressive prostate cancer models [1] Company Overview - Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapies that target the epigenetic and metabolic roots of cancer, aging, and age-related diseases [1]

Financial Performance - Telomir Pharmaceuticals reported net losses of $1.1 million for Q3 2025, compared to $6.0 million for Q3 2024, and $8.4 million for the nine months ended September 30, 2025, down from $13.7 million in the same period of 2024[80]. - The company has not generated any revenue and expects expenses to increase substantially as it advances preclinical activities and initiates clinical trials[79]. - The company has not generated any revenue since inception and does not anticipate doing so until successful completion of preclinical and clinical development and obtaining regulatory approval[101]. - The company incurred $2.5 million in negative cash flow from operations for the nine months ended September 30, 2025, compared to $4.5 million in 2024[111]. - As of September 30, 2025, the company had cash and cash equivalents of approximately $7.3 million and an accumulated deficit of approximately $38.9 million[111]. - The company expects its cash and cash equivalents to fund operations only through the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern[112]. Equity Financing - The company raised $3 million in equity financing through a direct investment, issuing 333,334 shares at $3.00 per share, an 18% premium to the closing price of $2.54 on the execution date[81]. - The company sold a total of 1,200,000 shares at an average price of $1.82 per share through its at-the-market equity offering facility[87]. - Financing activities provided $8.6 million of cash for the nine months ended September 30, 2025, primarily from the sale of common stock[119]. - The company entered into an agreement to raise $3 million in equity financing through a direct investment by The Bayshore Trust, issuing shares at a purchase price of $3.00 per share, representing an 18% premium to the closing share price on the date of execution[110]. Research and Development - Research and development expenses for the three months ended September 30, 2025, were $0.8 million, up from $0.6 million in the same period in 2024, primarily due to costs associated with the lead investigational therapy, Telomir-1[99]. - For the nine months ended September 30, 2025, research and development expenses totaled $1.1 million, a decrease from $1.9 million in the same period in 2024, attributed to certain pharmaceutical manufacturing activities not performed in 2025[100]. Product Development - A binding Letter of Intent was executed on October 17, 2025, to acquire TELI Pharmaceuticals, securing worldwide rights to Telomir-1, with potential contributions of up to $5 million from TELI shareholders[76][93]. - Telomir-1 demonstrated significant preclinical efficacy, including reversing DNA methylation of tumor suppressor genes and inhibiting aggressive cancer cell viability in various models[92][90]. - The company reported that Telomir-1 improved neuromotor performance and reduced liver-copper accumulation in a Wilson's disease model, indicating multi-organ protective effects[74]. - Telomir-1 showed the ability to restore mitochondrial function without triggering oxidative stress in human cells derived from a Progeria patient[84]. - Telomir-1's mechanism includes modulation of essential metal ions and epigenetic remodeling, which are believed to underlie aging, cancer, and metabolic dysfunction[75]. - Telomir-1 has not been evaluated in humans, and there is no assurance that preclinical results will translate into clinical safety or efficacy[75]. Administrative Expenses - General and administrative expenses for the three months ended September 30, 2025, were $0.4 million, down from $5.4 million in 2024, mainly due to stock-based compensation related to grants issued in 2024[105]. - For the nine months ended September 30, 2025, general and administrative expenses were $7.3 million, compared to $7.0 million in 2024, with the increase primarily due to executive stock-based compensation[105].

Core Insights - New findings indicate that Telomir-1 significantly impacts CASP8 and GSTP1, which are essential genes involved in regulating cell death and detoxification pathways often altered in cancer [1] Company Summary - Telomir Pharmaceuticals, Inc. is a pre-clinical biotechnology company focused on developing therapies that address the epigenetic causes of cancer, aging, and age-related diseases [1] - The company reported new preclinical data from an in vivo study involving mice with human aggressive prostate cancer tumors [1] Research Findings - The study evaluated DNA-methylation changes in the defense genes CASP8 and GSTP1 after treatment with oral Telomir-1, Rapamycin, chemotherapy, and combination regimens [1]

Core Insights - Telomir Pharmaceuticals, Inc. has executed a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., which will secure worldwide rights to its lead investigational therapy, Telomir-1 [1] - The agreement aims to unify global IP rights and enable up to $5 million in potential shareholder contributions, strengthening Telomir's foundation for partnerships, licensing, and long-term value creation [1] Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies targeting epigenetic drivers of cancer, aging, and age-related diseases [1]

Core Insights - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) has seen a significant increase in stock price, rising 20.30% to $1.98, with a trading volume of 21.60 million shares compared to the average of 4.9 million shares [1][5]. Group 1: Drug Candidate Performance - The lead drug candidate, Telomir-1, has demonstrated a significant reduction in the viability of aggressive triple-negative breast cancer (TNBC) cells in laboratory studies, showing a clear, dose-dependent effect [2]. - Telomir-1's efficacy is linked to its ability to regulate cellular iron and energy balance, as evidenced by the recovery of cancer cells when iron was reintroduced [2]. Group 2: Mechanism of Action - Telomir-1 has been shown to reset abnormal DNA methylation patterns and restore balanced gene expression in cancer models, particularly in TNBC where iron-dependent enzymes contribute to aggressive cancer behavior [3]. Group 3: Future Plans - The company plans to expand its research to include additional cancer types, such as pancreatic cancer and leukemia, and will conduct further animal studies in preparation for an Investigational New Drug (IND) submission [4].

Market Overview - U.S. equity markets are experiencing a slight pullback after a week of record gains, with major indices consolidating amidst optimism around AI and macroeconomic uncertainties, particularly the government shutdown [1][2][11] - The S&P 500 is down approximately 0.3% from its record close of 6,753.72, while the Nasdaq Composite also fell around 0.3% after reaching 23,043.38 [2] Sector Performance - Year-to-date, the S&P 500 has gained 14.8%, with technology leading the way, alongside Basic Materials and Communication Services, which have seen gains of 28.90% and 24.18% respectively [3] - Energy and financial stocks are stable, benefiting from stable oil prices and favorable interest rate prospects, although there are concerns about market overheating, particularly regarding the "Magnificent Seven" megacaps [3] Upcoming Economic Events - The U.S. government shutdown is ongoing, limiting key economic data releases, which has heightened investor focus on other market drivers [4] - The Federal Reserve is a focal point, with a high probability (around 95%) of an October rate cut anticipated, as revealed in the minutes from the September meeting [5] Earnings Season - The third-quarter earnings season has begun, with Delta Air Lines reporting record revenue and a positive outlook, leading to a stock surge of over 4% [6] - PepsiCo's stock rose by 3.5% after exceeding Q3 estimates and announcing a CFO change, while major banks are expected to report a 7.9% year-over-year earnings growth rate for the S&P 500 [6] Notable Stock Movements - Nvidia reached an all-time intraday high of $195.30, climbing nearly 3% after a price target increase by an analyst, driven by increased demand for computing [7] - Advanced Micro Devices rose over 11% following a significant deal with OpenAI, while Cisco unveiled a new product aimed at AI data centers [7][8] Commodities Market - Gold futures pulled back about 1% but remain above $4,000 per ounce, with a year-to-date increase of over 50% [10] - Silver hit $50 for the first time since 1980, marking a 60% year-to-date gain, while crude oil prices retreated slightly to $61.35 per barrel [10]